Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

US Patent 11795164 · Granted Oct 24, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Substituted aminoquinolones as dgkalpha inhibitors for immune activation2025
Substituted aminoquinolones as dgkalpha inhibitors for immune activation2025
Substituted aminoquinolones as dgkalpha inhibitors for immune activation2025
Substituted aminoquinolones as dgkalpha inhibitors for immune activation2025
Substituted aminoquinolones as DGKalpha inhibitors for immune activation2024
Substituted aminoquinolones as DGKalpha inhibitors for immune activation2024
Substituted aminoquinolones as DGKalpha inhibitors for immune activation2024
Substituted aminothiazoles as DGKzeta inhibitors for immune activation2024
Substituted aminothiazoles as DGKzeta inhibitors for immune activation2024
Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer2024
ILDR2 antagonists and combinations thereof2023
3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides2023